Abstract 1539P
Background
Immunotherapy combined with trastuzumab, and chemotherapy have been recommended by the clinical guidelines of many countries as the first-line treatment for advanced HER2-positive G/GEJ adnocarcinoma. Combining chemotherapy with tislizumab and trastuzumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable HER2-positive GC/GEJC.
Methods
This study is a multicentre, single-arm, open-label phase II study. Patients with histologically confirmed cT2-4NxM0 or cTxN+M0, (TNM 8th edition), resectable GC/GEJC are eligible for this study. Neoadjuvant therapy will be administered for four cycles. The patients will receive tislelizumab and trastuzumab for 1 cycle (Q3W), followed by tislelizumab and trastuzumab combined with DOS (Docetaxel + Oxaliplatin + S-1) for 3 cycles (Q3W). Surgery is planned 4-6 weeks after preoperative treatment. Patients will receive adjuvant therapy starting within 4–6 weeks after surgery for 9 cycles. The primary endpoint was pathological complete response rate (pCR). Secondary endpoints included R0 resection rate, 1-year and 2-year event-free survival (EFS), overall survival (OS) and safety.
Results
From September 13, 2021, to May 05, 2023, 18 patients were enrolled, and the median follow up time was 9.2 months (0.1-20.0).11 patients completed surgery, and 5 patients were undergoing neoadjuvant therapy, 2 patients required organ preservation therapy. R0 resection rate was 100%, 6 patients (54.5%) achieved pCR, and 7 patients (63.6%) achieved MPR. Postoperative pathology showed that T stage decreased in 9 cases after neoadjuvant therapy, with a decrease rate of 81.8%. Median OS and EFS have not been reached. The most common AEs (grade ≥3) were anaemia in 1 (5.6%) and neutropenia in 1 case (5.6%). The immune-related adverse events were all grade 1. No treatment related deaths were reported.
Conclusions
According to the preliminary results, tislelizumab combined with trastuzumab and standard chemotherapy in the perioperative period of HER2-positive GC / EGJ have a good clinical benefit trend and controllable security.
Clinical trial identification
NCT04819971.
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital of Zhengzhou University.
Funding
BeiGene (Beijing) Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21